Lynkuet

Overview

elinzanetant

NK-1/NK-3 antagonist

• CYP3A4 substrate
• CYP3A4 inhibitor, weak
• CNS depression
• lowers seizure threshold

Contraindicated

• cisapride
Lynkuet (elinzanetant)

+

cisapride

1 interaction

Contraindicated

elinzanetant + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• eliglustat
Lynkuet (elinzanetant)

+

eliglustat

1 interaction

Contraindicated

elinzanetant + eliglustat

CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

Avoid/Use Alternative

• adagrasib
Lynkuet (elinzanetant)

+

adagrasib

1 interaction

Avoid/Use Alternative

elinzanetant + adagrasib

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• aldesleukin
Lynkuet (elinzanetant)

+

aldesleukin

1 interaction

Avoid/Use Alternative

elinzanetant + aldesleukin

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, seizures (additive effects)

• alprazolam
Lynkuet (elinzanetant)

+

alprazolam

1 interaction

Avoid/Use Alternative

elinzanetant + alprazolam

use alternative or monitor resp. rate; consider decr. alprazolam dose: combo may incr. levels of both drugs, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• amifampridine
Lynkuet (elinzanetant)

+

amifampridine

1 interaction

Avoid/Use Alternative

elinzanetant + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• apalutamide
Lynkuet (elinzanetant)

+

apalutamide

1 interaction

Avoid/Use Alternative

elinzanetant + apalutamide

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• atazanavir
Lynkuet (elinzanetant)

+

atazanavir

1 interaction

Avoid/Use Alternative

elinzanetant + atazanavir

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• bosentan
Lynkuet (elinzanetant)

+

bosentan

1 interaction

Avoid/Use Alternative

elinzanetant + bosentan

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• butalbital
Lynkuet (elinzanetant)

+

butalbital

1 interaction

Avoid/Use Alternative

elinzanetant + butalbital

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• carbamazepine
Lynkuet (elinzanetant)

+

carbamazepine

1 interaction

Avoid/Use Alternative

elinzanetant + carbamazepine

avoid combo: combo may incr. carbamazepine levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. elinzanetant levels, efficacy; may alter seizure control (hepatic metab. inhibited, additive effects; hepatic metab. induced; antagonistic effects, elinzanetant may decr. seizure threshold)

• cenobamate
Lynkuet (elinzanetant)

+

cenobamate

1 interaction

Avoid/Use Alternative

elinzanetant + cenobamate

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metab. induced; additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• ceritinib
Lynkuet (elinzanetant)

+

ceritinib

1 interaction

Avoid/Use Alternative

elinzanetant + ceritinib

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• chloramphenicol
Lynkuet (elinzanetant)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

elinzanetant + chloramphenicol

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• clarithromycin
Lynkuet (elinzanetant)

+

clarithromycin

1 interaction

Avoid/Use Alternative

elinzanetant + clarithromycin

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• clonidine
Lynkuet (elinzanetant)

+

clonidine

1 interaction

Avoid/Use Alternative

elinzanetant + clonidine

if ADHD use, avoid combo; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cobicistat
Lynkuet (elinzanetant)

+

cobicistat

1 interaction

Avoid/Use Alternative

elinzanetant + cobicistat

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• codeine
Lynkuet (elinzanetant)

+

codeine

1 interaction

Avoid/Use Alternative

elinzanetant + codeine

avoid combo if antitussive use; otherwise, use alternative or monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. codeine and active metabolite morphine levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite morphine, additive effects)

• colchicine
Lynkuet (elinzanetant)

+

colchicine

1 interaction

Avoid/Use Alternative

elinzanetant + colchicine

CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT or FMF: use alternative or consider decr. colchicine dose during and x14 days after elinzanetant use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited)

• dabrafenib
Lynkuet (elinzanetant)

+

dabrafenib

1 interaction

Avoid/Use Alternative

elinzanetant + dabrafenib

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• doxylamine
Lynkuet (elinzanetant)

+

doxylamine

1 interaction

Avoid/Use Alternative

elinzanetant + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• efavirenz
Lynkuet (elinzanetant)

+

efavirenz

1 interaction

Avoid/Use Alternative

elinzanetant + efavirenz

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• encorafenib
Lynkuet (elinzanetant)

+

encorafenib

1 interaction

Avoid/Use Alternative

elinzanetant + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. elinzanetant levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• enzalutamide
Lynkuet (elinzanetant)

+

enzalutamide

1 interaction

Avoid/Use Alternative

elinzanetant + enzalutamide

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• ethanol
Lynkuet (elinzanetant)

+

ethanol

1 interaction

Avoid/Use Alternative

elinzanetant + ethanol

avoid combo: coingestion of oral alcohol w/ elinzanetant may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• etravirine
Lynkuet (elinzanetant)

+

etravirine

1 interaction

Avoid/Use Alternative

elinzanetant + etravirine

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• fexinidazole
Lynkuet (elinzanetant)

+

fexinidazole

1 interaction

Avoid/Use Alternative

elinzanetant + fexinidazole

avoid combo: combo may decr. fexinidazole active metabolite levels, elinzanetant levels, efficacy (hepatic metab. inhibited, decr. conversion to fexinidazole active metabolites; hepatic metab. induced)

• fosphenytoin
Lynkuet (elinzanetant)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

elinzanetant + fosphenytoin

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metab. induced; additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• hydrocodone
Lynkuet (elinzanetant)

+

hydrocodone

1 interaction

Avoid/Use Alternative

elinzanetant + hydrocodone

avoid combo if antitussive use; otherwise, use alternative or monitor resp. rate, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. hydrocodone levels, risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• idelalisib
Lynkuet (elinzanetant)

+

idelalisib

1 interaction

Avoid/Use Alternative

elinzanetant + idelalisib

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• iohexol
Lynkuet (elinzanetant)

+

iohexol

1 interaction

Avoid/Use Alternative

elinzanetant + iohexol

avoid combo if intrathecal iohexol use: combo may incr. risk of seizures (additive effects)

• isocarboxazid
Lynkuet (elinzanetant)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

elinzanetant + isocarboxazid

use alternative during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• itraconazole
Lynkuet (elinzanetant)

+

itraconazole

1 interaction

Avoid/Use Alternative

elinzanetant + itraconazole

avoid combo during and x2wk after itraconazole tx: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ivosidenib
Lynkuet (elinzanetant)

+

ivosidenib

1 interaction

Avoid/Use Alternative

elinzanetant + ivosidenib

avoid combo: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. elinzanetant levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• kava
Lynkuet (elinzanetant)

+

kava

1 interaction

Avoid/Use Alternative

elinzanetant + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ketoconazole
Lynkuet (elinzanetant)

+

ketoconazole

1 interaction

Avoid/Use Alternative

elinzanetant + ketoconazole

avoid combo during and up to 1wk after ketoconazole tx: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• kratom
Lynkuet (elinzanetant)

+

kratom

1 interaction

Avoid/Use Alternative

elinzanetant + kratom

use alternative or monitor resp. rate: combo may incr. elinzanetant levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• levoketoconazole
Lynkuet (elinzanetant)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

elinzanetant + levoketoconazole

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lonafarnib
Lynkuet (elinzanetant)

+

lonafarnib

1 interaction

Avoid/Use Alternative

elinzanetant + lonafarnib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lopinavir/ritonavir
Lynkuet (elinzanetant)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

elinzanetant + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. elinzanetant levels, incr. risk of CNS depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metab. altered)

• lorlatinib
Lynkuet (elinzanetant)

+

lorlatinib

1 interaction

Avoid/Use Alternative

elinzanetant + lorlatinib

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• mavacamten
Lynkuet (elinzanetant)

+

mavacamten

1 interaction

Avoid/Use Alternative

elinzanetant + mavacamten

avoid combo: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. elinzanetant levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• meperidine
Lynkuet (elinzanetant)

+

meperidine

1 interaction

Avoid/Use Alternative

elinzanetant + meperidine

use alternative or monitor resp. rate, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. meperidine levels, risk of profound CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• metaxalone
Lynkuet (elinzanetant)

+

metaxalone

1 interaction

Avoid/Use Alternative

elinzanetant + metaxalone

use alternative or monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• methadone
Lynkuet (elinzanetant)

+

methadone

1 interaction

Avoid/Use Alternative

elinzanetant + methadone

use alternative or monitor resp. rate, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. methadone levels, risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• metoclopramide
Lynkuet (elinzanetant)

+

metoclopramide

1 interaction

Avoid/Use Alternative

elinzanetant + metoclopramide

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• midazolam
Lynkuet (elinzanetant)

+

midazolam

1 interaction

Avoid/Use Alternative

elinzanetant + midazolam

use alternative or monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx; caution advised if seizure disorder use: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metab. inhibited, additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• mifepristone
Lynkuet (elinzanetant)

+

mifepristone

1 interaction

Avoid/Use Alternative

elinzanetant + mifepristone

avoid combo during and x14 days after daily mifepristone use: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• mitapivat
Lynkuet (elinzanetant)

+

mitapivat

1 interaction

Avoid/Use Alternative

elinzanetant + mitapivat

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• mitotane
Lynkuet (elinzanetant)

+

mitotane

1 interaction

Avoid/Use Alternative

elinzanetant + mitotane

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• modafinil
Lynkuet (elinzanetant)

+

modafinil

1 interaction

Avoid/Use Alternative

elinzanetant + modafinil

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• nafcillin
Lynkuet (elinzanetant)

+

nafcillin

1 interaction

Avoid/Use Alternative

elinzanetant + nafcillin

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• nefazodone
Lynkuet (elinzanetant)

+

nefazodone

1 interaction

Avoid/Use Alternative

elinzanetant + nefazodone

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• nelfinavir
Lynkuet (elinzanetant)

+

nelfinavir

1 interaction

Avoid/Use Alternative

elinzanetant + nelfinavir

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• oxybate
Lynkuet (elinzanetant)

+

oxybate

1 interaction

Avoid/Use Alternative

elinzanetant + oxybate

use alternative or monitor resp. rate, BP; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects)

• oxycodone
Lynkuet (elinzanetant)

+

oxycodone

1 interaction

Avoid/Use Alternative

elinzanetant + oxycodone

use alternative or monitor resp. rate; decr. oxycodone start dose by at least 50%, consider decr. elinzanetant dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• pacritinib
Lynkuet (elinzanetant)

+

pacritinib

1 interaction

Avoid/Use Alternative

elinzanetant + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (incl. life-threatening), other adverse effects; may decr. elinzanetant levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• pentobarbital
Lynkuet (elinzanetant)

+

pentobarbital

1 interaction

Avoid/Use Alternative

elinzanetant + pentobarbital

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• pexidartinib
Lynkuet (elinzanetant)

+

pexidartinib

1 interaction

Avoid/Use Alternative

elinzanetant + pexidartinib

avoid combo: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. elinzanetant levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• phenelzine
Lynkuet (elinzanetant)

+

phenelzine

1 interaction

Avoid/Use Alternative

elinzanetant + phenelzine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• phenobarbital
Lynkuet (elinzanetant)

+

phenobarbital

1 interaction

Avoid/Use Alternative

elinzanetant + phenobarbital

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metab. induced; additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• phenytoin
Lynkuet (elinzanetant)

+

phenytoin

1 interaction

Avoid/Use Alternative

elinzanetant + phenytoin

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metab. induced; additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• pimozide
Lynkuet (elinzanetant)

+

pimozide

1 interaction

Avoid/Use Alternative

elinzanetant + pimozide

use alternative or monitor ECG: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• posaconazole
Lynkuet (elinzanetant)

+

posaconazole

1 interaction

Avoid/Use Alternative

elinzanetant + posaconazole

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• pralsetinib
Lynkuet (elinzanetant)

+

pralsetinib

1 interaction

Avoid/Use Alternative

elinzanetant + pralsetinib

if also combined w/ P-gp inhibitor, use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd; otherwise, consider monitoring ECG, electrolytes: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• primidone
Lynkuet (elinzanetant)

+

primidone

1 interaction

Avoid/Use Alternative

elinzanetant + primidone

avoid combo: combo may decr. elinzanetant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metab. induced; additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• promethazine
Lynkuet (elinzanetant)

+

promethazine

1 interaction

Avoid/Use Alternative

elinzanetant + promethazine

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment, seizures (additive effects)

• propafenone
Lynkuet (elinzanetant)

+

propafenone

1 interaction

Avoid/Use Alternative

elinzanetant + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metab. inhibited)

• repotrectinib
Lynkuet (elinzanetant)

+

repotrectinib

1 interaction

Avoid/Use Alternative

elinzanetant + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. elinzanetant levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• ribociclib
Lynkuet (elinzanetant)

+

ribociclib

1 interaction

Avoid/Use Alternative

elinzanetant + ribociclib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• rifapentine
Lynkuet (elinzanetant)

+

rifapentine

1 interaction

Avoid/Use Alternative

elinzanetant + rifapentine

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• ritonavir
Lynkuet (elinzanetant)

+

ritonavir

1 interaction

Avoid/Use Alternative

elinzanetant + ritonavir

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ropeginterferon alfa-2b
Lynkuet (elinzanetant)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

elinzanetant + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• simvastatin
Lynkuet (elinzanetant)

+

simvastatin

1 interaction

Avoid/Use Alternative

elinzanetant + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• sotorasib
Lynkuet (elinzanetant)

+

sotorasib

1 interaction

Avoid/Use Alternative

elinzanetant + sotorasib

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metab. induced)

• thalidomide
Lynkuet (elinzanetant)

+

thalidomide

1 interaction

Avoid/Use Alternative

elinzanetant + thalidomide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tipranavir
Lynkuet (elinzanetant)

+

tipranavir

1 interaction

Avoid/Use Alternative

elinzanetant + tipranavir

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• tranylcypromine
Lynkuet (elinzanetant)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

elinzanetant + tranylcypromine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimethobenzamide
Lynkuet (elinzanetant)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

elinzanetant + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tucatinib
Lynkuet (elinzanetant)

+

tucatinib

1 interaction

Avoid/Use Alternative

elinzanetant + tucatinib

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• voriconazole
Lynkuet (elinzanetant)

+

voriconazole

1 interaction

Avoid/Use Alternative

elinzanetant + voriconazole

avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• zuranolone
Lynkuet (elinzanetant)

+

zuranolone

1 interaction

Avoid/Use Alternative

elinzanetant + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• abemaciclib
Lynkuet (elinzanetant)

+

abemaciclib

1 interaction

Monitor/Modify Tx

elinzanetant + abemaciclib

monitor CBC: combo may incr. abemaciclib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• acalabrutinib
Lynkuet (elinzanetant)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

elinzanetant + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• alfentanil
Lynkuet (elinzanetant)

+

alfentanil

1 interaction

Monitor/Modify Tx

elinzanetant + alfentanil

monitor BP, resp. rate; decr. dose of one or both drugs: combo may incr. alfentanil levels, risk of profound CNS and resp. depression, psychomotor impairment, hypotension, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited, additive effects)

• amiodarone
Lynkuet (elinzanetant)

+

amiodarone

1 interaction

Monitor/Modify Tx

elinzanetant + amiodarone

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• aprepitant
Lynkuet (elinzanetant)

+

aprepitant

1 interaction

Monitor/Modify Tx

elinzanetant + aprepitant

if aprepitant 3-day regimen, decr. elinzanetant dose to 60 mg daily; aprepitant single dose-regimen OK: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• avacopan
Lynkuet (elinzanetant)

+

avacopan

1 interaction

Monitor/Modify Tx

elinzanetant + avacopan

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• avanafil
Lynkuet (elinzanetant)

+

avanafil

1 interaction

Monitor/Modify Tx

elinzanetant + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avapritinib
Lynkuet (elinzanetant)

+

avapritinib

1 interaction

Monitor/Modify Tx

elinzanetant + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• baclofen intrathecal
Lynkuet (elinzanetant)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

elinzanetant + baclofen intrathecal

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• berotralstat
Lynkuet (elinzanetant)

+

berotralstat

1 interaction

Monitor/Modify Tx

elinzanetant + berotralstat

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• brigatinib
Lynkuet (elinzanetant)

+

brigatinib

1 interaction

Monitor/Modify Tx

elinzanetant + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metab. inhibited)

• buprenorphine
Lynkuet (elinzanetant)

+

buprenorphine

1 interaction

Monitor/Modify Tx

elinzanetant + buprenorphine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• bupropion
Lynkuet (elinzanetant)

+

bupropion

1 interaction

Monitor/Modify Tx

elinzanetant + bupropion

consider lower bupropion doses: combo may incr. risk of seizures (additive effects)

• butorphanol
Lynkuet (elinzanetant)

+

butorphanol

1 interaction

Monitor/Modify Tx

elinzanetant + butorphanol

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• capivasertib
Lynkuet (elinzanetant)

+

capivasertib

1 interaction

Monitor/Modify Tx

elinzanetant + capivasertib

monitor glucose: combo may incr. levels of both drugs, risk of severe hyperglycemia, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• chlordiazepoxide
Lynkuet (elinzanetant)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

elinzanetant + chlordiazepoxide

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• chlorpromazine
Lynkuet (elinzanetant)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

elinzanetant + chlorpromazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ciprofloxacin
Lynkuet (elinzanetant)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

elinzanetant + ciprofloxacin

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• clobazam
Lynkuet (elinzanetant)

+

clobazam

1 interaction

Monitor/Modify Tx

elinzanetant + clobazam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• clofazimine
Lynkuet (elinzanetant)

+

clofazimine

1 interaction

Monitor/Modify Tx

elinzanetant + clofazimine

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• clonazepam
Lynkuet (elinzanetant)

+

clonazepam

1 interaction

Monitor/Modify Tx

elinzanetant + clonazepam

monitor resp. rate; caution advised if seizure disorder use: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• clorazepate
Lynkuet (elinzanetant)

+

clorazepate

1 interaction

Monitor/Modify Tx

elinzanetant + clorazepate

monitor resp. rate; caution advised if seizure disorder use: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• clozapine
Lynkuet (elinzanetant)

+

clozapine

1 interaction

Monitor/Modify Tx

elinzanetant + clozapine

monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, CNS depression, psychomotor impairment, seizures, other adverse effects (hepatic metab. inhibited, additive effects)

• conivaptan
Lynkuet (elinzanetant)

+

conivaptan

1 interaction

Monitor/Modify Tx

elinzanetant + conivaptan

decr. elinzanetant dose to 60 mg daily during and x7 days after conivaptan tx: combo may incr. levels of both drugs, risk of overly rapid serum sodium correction, neurologic sequelae, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• crizotinib
Lynkuet (elinzanetant)

+

crizotinib

1 interaction

Monitor/Modify Tx

elinzanetant + crizotinib

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• cyclosporine
Lynkuet (elinzanetant)

+

cyclosporine

1 interaction

Monitor/Modify Tx

elinzanetant + cyclosporine

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• danazol
Lynkuet (elinzanetant)

+

danazol

1 interaction

Monitor/Modify Tx

elinzanetant + danazol

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• daridorexant
Lynkuet (elinzanetant)

+

daridorexant

1 interaction

Monitor/Modify Tx

elinzanetant + daridorexant

consider decr. dose of one or both drugs: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• darunavir
Lynkuet (elinzanetant)

+

darunavir

1 interaction

Monitor/Modify Tx

elinzanetant + darunavir

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• desflurane
Lynkuet (elinzanetant)

+

desflurane

1 interaction

Monitor/Modify Tx

elinzanetant + desflurane

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• dexmedetomidine
Lynkuet (elinzanetant)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

elinzanetant + dexmedetomidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Lynkuet (elinzanetant)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

elinzanetant + dexmedetomidine injection

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• diazepam
Lynkuet (elinzanetant)

+

diazepam

1 interaction

Monitor/Modify Tx

elinzanetant + diazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx; caution advised if seizure disorder use: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• dihydrocodeine
Lynkuet (elinzanetant)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

elinzanetant + dihydrocodeine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• diltiazem
Lynkuet (elinzanetant)

+

diltiazem

1 interaction

Monitor/Modify Tx

elinzanetant + diltiazem

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• disopyramide
Lynkuet (elinzanetant)

+

disopyramide

1 interaction

Monitor/Modify Tx

elinzanetant + disopyramide

monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• docetaxel
Lynkuet (elinzanetant)

+

docetaxel

1 interaction

Monitor/Modify Tx

elinzanetant + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dofetilide
Lynkuet (elinzanetant)

+

dofetilide

1 interaction

Monitor/Modify Tx

elinzanetant + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• domperidone
Lynkuet (elinzanetant)

+

domperidone

1 interaction

Monitor/Modify Tx

elinzanetant + domperidone

monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• dronedarone
Lynkuet (elinzanetant)

+

dronedarone

1 interaction

Monitor/Modify Tx

elinzanetant + dronedarone

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• droperidol
Lynkuet (elinzanetant)

+

droperidol

1 interaction

Monitor/Modify Tx

elinzanetant + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• duvelisib
Lynkuet (elinzanetant)

+

duvelisib

1 interaction

Monitor/Modify Tx

elinzanetant + duvelisib

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• entrectinib
Lynkuet (elinzanetant)

+

entrectinib

1 interaction

Monitor/Modify Tx

elinzanetant + entrectinib

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• erythromycin
Lynkuet (elinzanetant)

+

erythromycin

1 interaction

Monitor/Modify Tx

elinzanetant + erythromycin

monitor ECG; decr. elinzanetant dose to 60 mg daily: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• esketamine
Lynkuet (elinzanetant)

+

esketamine

1 interaction

Monitor/Modify Tx

elinzanetant + esketamine

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• estazolam
Lynkuet (elinzanetant)

+

estazolam

1 interaction

Monitor/Modify Tx

elinzanetant + estazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• eszopiclone
Lynkuet (elinzanetant)

+

eszopiclone

1 interaction

Monitor/Modify Tx

elinzanetant + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethanol (in some formulations)
Lynkuet (elinzanetant)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

elinzanetant + ethanol (in some formulations)

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• etomidate
Lynkuet (elinzanetant)

+

etomidate

1 interaction

Monitor/Modify Tx

elinzanetant + etomidate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• everolimus
Lynkuet (elinzanetant)

+

everolimus

1 interaction

Monitor/Modify Tx

elinzanetant + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. levels of both drugs, risk of myelosuppression, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• fedratinib
Lynkuet (elinzanetant)

+

fedratinib

1 interaction

Monitor/Modify Tx

elinzanetant + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs; decr. elinzanetant dose to 60 mg daily: combo may incr. levels of both drugs, risk of myelosuppression, hepatotoxicity, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• felodipine
Lynkuet (elinzanetant)

+

felodipine

1 interaction

Monitor/Modify Tx

elinzanetant + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metab. inhibited)

• fentanyl
Lynkuet (elinzanetant)

+

fentanyl

1 interaction

Monitor/Modify Tx

elinzanetant + fentanyl

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. fentanyl levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• finerenone
Lynkuet (elinzanetant)

+

finerenone

1 interaction

Monitor/Modify Tx

elinzanetant + finerenone

monitor potassium; caution advised if on finerenone 40 mg/day: combo may incr. levels of both drugs, risk of hyperkalemia, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• flibanserin
Lynkuet (elinzanetant)

+

flibanserin

1 interaction

Monitor/Modify Tx

elinzanetant + flibanserin

monitor BP, especially if flibanserin also combined w/ other weak CYP3A4 inhibitors: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects (hepatic metab. inhibited, additive effects)

• fluconazole
Lynkuet (elinzanetant)

+

fluconazole

1 interaction

Monitor/Modify Tx

elinzanetant + fluconazole

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• fluphenazine
Lynkuet (elinzanetant)

+

fluphenazine

1 interaction

Monitor/Modify Tx

elinzanetant + fluphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• flurazepam
Lynkuet (elinzanetant)

+

flurazepam

1 interaction

Monitor/Modify Tx

elinzanetant + flurazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• fosamprenavir
Lynkuet (elinzanetant)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

elinzanetant + fosamprenavir

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• gabapentin
Lynkuet (elinzanetant)

+

gabapentin

1 interaction

Monitor/Modify Tx

elinzanetant + gabapentin

monitor resp. rate; caution advised if seizure disorder use: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• gabapentin enacarbil
Lynkuet (elinzanetant)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

elinzanetant + gabapentin enacarbil

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• gepirone
Lynkuet (elinzanetant)

+

gepirone

1 interaction

Monitor/Modify Tx

elinzanetant + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• grapefruit
Lynkuet (elinzanetant)

+

grapefruit

1 interaction

Monitor/Modify Tx

elinzanetant + grapefruit

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metab. inhibited)

• hydromorphone
Lynkuet (elinzanetant)

+

hydromorphone

1 interaction

Monitor/Modify Tx

elinzanetant + hydromorphone

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• hydroxyzine
Lynkuet (elinzanetant)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

elinzanetant + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ibrutinib
Lynkuet (elinzanetant)

+

ibrutinib

1 interaction

Monitor/Modify Tx

elinzanetant + ibrutinib

consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ifosfamide
Lynkuet (elinzanetant)

+

ifosfamide

1 interaction

Monitor/Modify Tx

elinzanetant + ifosfamide

D/C one or both drugs if encephalopathy occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• imatinib
Lynkuet (elinzanetant)

+

imatinib

1 interaction

Monitor/Modify Tx

elinzanetant + imatinib

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• iopamidol
Lynkuet (elinzanetant)

+

iopamidol

1 interaction

Monitor/Modify Tx

elinzanetant + iopamidol

caution advised if intrathecal iopamidol use; consider holding elinzanetant at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• isavuconazonium
Lynkuet (elinzanetant)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

elinzanetant + isavuconazonium

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• isoflurane
Lynkuet (elinzanetant)

+

isoflurane

1 interaction

Monitor/Modify Tx

elinzanetant + isoflurane

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• ivabradine
Lynkuet (elinzanetant)

+

ivabradine

1 interaction

Monitor/Modify Tx

elinzanetant + ivabradine

monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ixabepilone
Lynkuet (elinzanetant)

+

ixabepilone

1 interaction

Monitor/Modify Tx

elinzanetant + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited)

• ketamine
Lynkuet (elinzanetant)

+

ketamine

1 interaction

Monitor/Modify Tx

elinzanetant + ketamine

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression (incl. life-threatening), psychomotor impairment (additive effects)

• lefamulin
Lynkuet (elinzanetant)

+

lefamulin

1 interaction

Monitor/Modify Tx

elinzanetant + lefamulin

ORAL LEFAMULIN: decr. elinzanetant dose to 60 mg daily; IV lefamulin use OK: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lemborexant
Lynkuet (elinzanetant)

+

lemborexant

1 interaction

Monitor/Modify Tx

elinzanetant + lemborexant

adjust max lemborexant dose to 5 mg/day; consider decr. elinzanetant dose: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• lenacapavir
Lynkuet (elinzanetant)

+

lenacapavir

1 interaction

Monitor/Modify Tx

elinzanetant + lenacapavir

decr. elinzanetant dose to 60 mg daily during and x9mo after lenacapavir tx: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• letermovir
Lynkuet (elinzanetant)

+

letermovir

1 interaction

Monitor/Modify Tx

elinzanetant + letermovir

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• levorphanol
Lynkuet (elinzanetant)

+

levorphanol

1 interaction

Monitor/Modify Tx

elinzanetant + levorphanol

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• lomitapide
Lynkuet (elinzanetant)

+

lomitapide

1 interaction

Monitor/Modify Tx

elinzanetant + lomitapide

adjust max lomitapide dose to 30 mg/day: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lorazepam
Lynkuet (elinzanetant)

+

lorazepam

1 interaction

Monitor/Modify Tx

elinzanetant + lorazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx; caution advised if seizure disorder use: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• lovastatin
Lynkuet (elinzanetant)

+

lovastatin

1 interaction

Monitor/Modify Tx

elinzanetant + lovastatin

monitor CK, myopathy sx: combo may incr. levels of both drugs, risk of myopathy, rhabdomyolysis, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lumateperone
Lynkuet (elinzanetant)

+

lumateperone

1 interaction

Monitor/Modify Tx

elinzanetant + lumateperone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• lurasidone
Lynkuet (elinzanetant)

+

lurasidone

1 interaction

Monitor/Modify Tx

elinzanetant + lurasidone

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• lurbinectedin
Lynkuet (elinzanetant)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

elinzanetant + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• methohexital
Lynkuet (elinzanetant)

+

methohexital

1 interaction

Monitor/Modify Tx

elinzanetant + methohexital

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• mirtazapine
Lynkuet (elinzanetant)

+

mirtazapine

1 interaction

Monitor/Modify Tx

elinzanetant + mirtazapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mobocertinib
Lynkuet (elinzanetant)

+

mobocertinib

1 interaction

Monitor/Modify Tx

elinzanetant + mobocertinib

monitor ECG: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• morphine
Lynkuet (elinzanetant)

+

morphine

1 interaction

Monitor/Modify Tx

elinzanetant + morphine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• nalbuphine
Lynkuet (elinzanetant)

+

nalbuphine

1 interaction

Monitor/Modify Tx

elinzanetant + nalbuphine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• nelarabine
Lynkuet (elinzanetant)

+

nelarabine

1 interaction

Monitor/Modify Tx

elinzanetant + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• netupitant
Lynkuet (elinzanetant)

+

netupitant

1 interaction

Monitor/Modify Tx

elinzanetant + netupitant

decr. elinzanetant dose to 60 mg daily during and x1wk after (fos)netupitant tx: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• nifedipine
Lynkuet (elinzanetant)

+

nifedipine

1 interaction

Monitor/Modify Tx

elinzanetant + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nilotinib
Lynkuet (elinzanetant)

+

nilotinib

1 interaction

Monitor/Modify Tx

elinzanetant + nilotinib

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• nimodipine
Lynkuet (elinzanetant)

+

nimodipine

1 interaction

Monitor/Modify Tx

elinzanetant + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nirogacestat
Lynkuet (elinzanetant)

+

nirogacestat

1 interaction

Monitor/Modify Tx

elinzanetant + nirogacestat

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• nisoldipine
Lynkuet (elinzanetant)

+

nisoldipine

1 interaction

Monitor/Modify Tx

elinzanetant + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• olanzapine
Lynkuet (elinzanetant)

+

olanzapine

1 interaction

Monitor/Modify Tx

elinzanetant + olanzapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, incl. orthostasis (additive effects)

• oliceridine
Lynkuet (elinzanetant)

+

oliceridine

1 interaction

Monitor/Modify Tx

elinzanetant + oliceridine

monitor resp. rate, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. oliceridine levels, risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• opicapone
Lynkuet (elinzanetant)

+

opicapone

1 interaction

Monitor/Modify Tx

elinzanetant + opicapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• opium
Lynkuet (elinzanetant)

+

opium

1 interaction

Monitor/Modify Tx

elinzanetant + opium

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• oxazepam
Lynkuet (elinzanetant)

+

oxazepam

1 interaction

Monitor/Modify Tx

elinzanetant + oxazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• oxybutynin
Lynkuet (elinzanetant)

+

oxybutynin

1 interaction

Monitor/Modify Tx

elinzanetant + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely w/ oxybutynin transdermal patch (additive effects)

• oxymorphone
Lynkuet (elinzanetant)

+

oxymorphone

1 interaction

Monitor/Modify Tx

elinzanetant + oxymorphone

monitor resp. rate; decr. oxymorphone start dose by at least 50%, consider decr. elinzanetant dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• pemigatinib
Lynkuet (elinzanetant)

+

pemigatinib

1 interaction

Monitor/Modify Tx

elinzanetant + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• pentazocine
Lynkuet (elinzanetant)

+

pentazocine

1 interaction

Monitor/Modify Tx

elinzanetant + pentazocine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• perphenazine
Lynkuet (elinzanetant)

+

perphenazine

1 interaction

Monitor/Modify Tx

elinzanetant + perphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pregabalin
Lynkuet (elinzanetant)

+

pregabalin

1 interaction

Monitor/Modify Tx

elinzanetant + pregabalin

monitor resp. rate; caution advised if seizure disorder use: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• propofol
Lynkuet (elinzanetant)

+

propofol

1 interaction

Monitor/Modify Tx

elinzanetant + propofol

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quazepam
Lynkuet (elinzanetant)

+

quazepam

1 interaction

Monitor/Modify Tx

elinzanetant + quazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quinidine (antiarrhythmic)
Lynkuet (elinzanetant)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

elinzanetant + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• red yeast rice
Lynkuet (elinzanetant)

+

red yeast rice

1 interaction

Monitor/Modify Tx

elinzanetant + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, red yeast rice contains varying amounts of lovastatin)

• remifentanil
Lynkuet (elinzanetant)

+

remifentanil

1 interaction

Monitor/Modify Tx

elinzanetant + remifentanil

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• remimazolam
Lynkuet (elinzanetant)

+

remimazolam

1 interaction

Monitor/Modify Tx

elinzanetant + remimazolam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• rilzabrutinib
Lynkuet (elinzanetant)

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

elinzanetant + rilzabrutinib

decr. elinzanetant dose to 60 mg daily: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• selpercatinib
Lynkuet (elinzanetant)

+

selpercatinib

1 interaction

Monitor/Modify Tx

elinzanetant + selpercatinib

monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• selumetinib
Lynkuet (elinzanetant)

+

selumetinib

1 interaction

Monitor/Modify Tx

elinzanetant + selumetinib

monitor LVEF, CK, myopathy sx: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• sevoflurane
Lynkuet (elinzanetant)

+

sevoflurane

1 interaction

Monitor/Modify Tx

elinzanetant + sevoflurane

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• sirolimus
Lynkuet (elinzanetant)

+

sirolimus

1 interaction

Monitor/Modify Tx

elinzanetant + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metab. inhibited)

• sirolimus albumin-bound
Lynkuet (elinzanetant)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

elinzanetant + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• sufentanil
Lynkuet (elinzanetant)

+

sufentanil

1 interaction

Monitor/Modify Tx

elinzanetant + sufentanil

monitor resp. rate; decr. sufentanil start dose, consider decr. elinzanetant dose, use lowest effective doses: combo may incr. sufentanil levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• suvorexant
Lynkuet (elinzanetant)

+

suvorexant

1 interaction

Monitor/Modify Tx

elinzanetant + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tacrolimus
Lynkuet (elinzanetant)

+

tacrolimus

1 interaction

Monitor/Modify Tx

elinzanetant + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited)

• tadalafil
Lynkuet (elinzanetant)

+

tadalafil

1 interaction

Monitor/Modify Tx

elinzanetant + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• taletrectinib
Lynkuet (elinzanetant)

+

taletrectinib

1 interaction

Monitor/Modify Tx

elinzanetant + taletrectinib

monitor ECG: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• tapentadol
Lynkuet (elinzanetant)

+

tapentadol

1 interaction

Monitor/Modify Tx

elinzanetant + tapentadol

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• temazepam
Lynkuet (elinzanetant)

+

temazepam

1 interaction

Monitor/Modify Tx

elinzanetant + temazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• temsirolimus
Lynkuet (elinzanetant)

+

temsirolimus

1 interaction

Monitor/Modify Tx

elinzanetant + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• thioridazine
Lynkuet (elinzanetant)

+

thioridazine

1 interaction

Monitor/Modify Tx

elinzanetant + thioridazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiothixene
Lynkuet (elinzanetant)

+

thiothixene

1 interaction

Monitor/Modify Tx

elinzanetant + thiothixene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolvaptan
Lynkuet (elinzanetant)

+

tolvaptan

1 interaction

Monitor/Modify Tx

elinzanetant + tolvaptan

consider decr. tolvaptan dose: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• tramadol
Lynkuet (elinzanetant)

+

tramadol

1 interaction

Monitor/Modify Tx

elinzanetant + tramadol

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, seizures (additive effects)

• triazolam
Lynkuet (elinzanetant)

+

triazolam

1 interaction

Monitor/Modify Tx

elinzanetant + triazolam

monitor resp. rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• ubrogepant
Lynkuet (elinzanetant)

+

ubrogepant

1 interaction

Monitor/Modify Tx

elinzanetant + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited)

• vardenafil
Lynkuet (elinzanetant)

+

vardenafil

1 interaction

Monitor/Modify Tx

elinzanetant + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• venetoclax
Lynkuet (elinzanetant)

+

venetoclax

1 interaction

Monitor/Modify Tx

elinzanetant + venetoclax

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited)

• verapamil
Lynkuet (elinzanetant)

+

verapamil

1 interaction

Monitor/Modify Tx

elinzanetant + verapamil

monitor BP, HR; decr. elinzanetant dose to 60 mg daily: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• vinblastine
Lynkuet (elinzanetant)

+

vinblastine

1 interaction

Monitor/Modify Tx

elinzanetant + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vincristine
Lynkuet (elinzanetant)

+

vincristine

1 interaction

Monitor/Modify Tx

elinzanetant + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinorelbine
Lynkuet (elinzanetant)

+

vinorelbine

1 interaction

Monitor/Modify Tx

elinzanetant + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• warfarin
Lynkuet (elinzanetant)

+

warfarin

1 interaction

Monitor/Modify Tx

elinzanetant + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• zaleplon
Lynkuet (elinzanetant)

+

zaleplon

1 interaction

Monitor/Modify Tx

elinzanetant + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zanubrutinib
Lynkuet (elinzanetant)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

elinzanetant + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection; myelosuppression, other adverse effects (hepatic metab. inhibited)

• ziconotide
Lynkuet (elinzanetant)

+

ziconotide

1 interaction

Monitor/Modify Tx

elinzanetant + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Lynkuet (elinzanetant)

+

zolpidem

1 interaction

Monitor/Modify Tx

elinzanetant + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Caution Advised

• 5-HTP
Lynkuet (elinzanetant)

+

5-HTP

1 interaction

Caution Advised

elinzanetant + 5-HTP

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• acetazolamide
Lynkuet (elinzanetant)

+

acetazolamide

1 interaction

Caution Advised

elinzanetant + acetazolamide

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, elinzanetant may decr. seizure threshold)

• allopurinol
Lynkuet (elinzanetant)

+

allopurinol

1 interaction

Caution Advised

elinzanetant + allopurinol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• almotriptan
Lynkuet (elinzanetant)

+

almotriptan

1 interaction

Caution Advised

elinzanetant + almotriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amantadine
Lynkuet (elinzanetant)

+

amantadine

1 interaction

Caution Advised

elinzanetant + amantadine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amitriptyline
Lynkuet (elinzanetant)

+

amitriptyline

1 interaction

Caution Advised

elinzanetant + amitriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amlodipine
Lynkuet (elinzanetant)

+

amlodipine

1 interaction

Caution Advised

elinzanetant + amlodipine

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• amoxapine
Lynkuet (elinzanetant)

+

amoxapine

1 interaction

Caution Advised

elinzanetant + amoxapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• apomorphine
Lynkuet (elinzanetant)

+

apomorphine

1 interaction

Caution Advised

elinzanetant + apomorphine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• apraclonidine ophthalmic
Lynkuet (elinzanetant)

+

apraclonidine ophthalmic

1 interaction

Caution Advised

elinzanetant + apraclonidine ophthalmic

caution advised if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole bimonthly injection
Lynkuet (elinzanetant)

+

aripiprazole bimonthly injection

1 interaction

Caution Advised

elinzanetant + aripiprazole bimonthly injection

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole lauroxil
Lynkuet (elinzanetant)

+

aripiprazole lauroxil

1 interaction

Caution Advised

elinzanetant + aripiprazole lauroxil

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole monthly injection
Lynkuet (elinzanetant)

+

aripiprazole monthly injection

1 interaction

Caution Advised

elinzanetant + aripiprazole monthly injection

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole oral
Lynkuet (elinzanetant)

+

aripiprazole oral

1 interaction

Caution Advised

elinzanetant + aripiprazole oral

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• asciminib
Lynkuet (elinzanetant)

+

asciminib

1 interaction

Caution Advised

elinzanetant + asciminib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• asenapine
Lynkuet (elinzanetant)

+

asenapine

1 interaction

Caution Advised

elinzanetant + asenapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• atorvastatin
Lynkuet (elinzanetant)

+

atorvastatin

1 interaction

Caution Advised

elinzanetant + atorvastatin

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• baclofen
Lynkuet (elinzanetant)

+

baclofen

1 interaction

Caution Advised

elinzanetant + baclofen

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• belumosudil
Lynkuet (elinzanetant)

+

belumosudil

1 interaction

Caution Advised

elinzanetant + belumosudil

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• berberine
Lynkuet (elinzanetant)

+

berberine

1 interaction

Caution Advised

elinzanetant + berberine

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• bicalutamide
Lynkuet (elinzanetant)

+

bicalutamide

1 interaction

Caution Advised

elinzanetant + bicalutamide

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• brexpiprazole
Lynkuet (elinzanetant)

+

brexpiprazole

1 interaction

Caution Advised

elinzanetant + brexpiprazole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brimonidine ophthalmic
Lynkuet (elinzanetant)

+

brimonidine ophthalmic

1 interaction

Caution Advised

elinzanetant + brimonidine ophthalmic

caution advised if elevated IOP use; OTC ocular redness use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brimonidine topical
Lynkuet (elinzanetant)

+

brimonidine topical

1 interaction

Caution Advised

elinzanetant + brimonidine topical

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brivaracetam
Lynkuet (elinzanetant)

+

brivaracetam

1 interaction

Caution Advised

elinzanetant + brivaracetam

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• bromocriptine
Lynkuet (elinzanetant)

+

bromocriptine

1 interaction

Caution Advised

elinzanetant + bromocriptine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brompheniramine
Lynkuet (elinzanetant)

+

brompheniramine

1 interaction

Caution Advised

elinzanetant + brompheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• buspirone
Lynkuet (elinzanetant)

+

buspirone

1 interaction

Caution Advised

elinzanetant + buspirone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• busulfan
Lynkuet (elinzanetant)

+

busulfan

1 interaction

Caution Advised

elinzanetant + busulfan

caution advised: combo may incr. risk of seizures (additive effects)

• cannabidiol
Lynkuet (elinzanetant)

+

cannabidiol

1 interaction

Caution Advised

elinzanetant + cannabidiol

caution advised if seizure disorder use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• cannabis
Lynkuet (elinzanetant)

+

cannabis

1 interaction

Caution Advised

elinzanetant + cannabis

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• carbinoxamine
Lynkuet (elinzanetant)

+

carbinoxamine

1 interaction

Caution Advised

elinzanetant + carbinoxamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cariprazine
Lynkuet (elinzanetant)

+

cariprazine

1 interaction

Caution Advised

elinzanetant + cariprazine

caution advised: combo may incr. cariprazine and active metabolite levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• carisoprodol
Lynkuet (elinzanetant)

+

carisoprodol

1 interaction

Caution Advised

elinzanetant + carisoprodol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cetirizine
Lynkuet (elinzanetant)

+

cetirizine

1 interaction

Caution Advised

elinzanetant + cetirizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chamomile, German
Lynkuet (elinzanetant)

+

chamomile, German

1 interaction

Caution Advised

elinzanetant + chamomile, German

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlophedianol
Lynkuet (elinzanetant)

+

chlophedianol

1 interaction

Caution Advised

elinzanetant + chlophedianol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorambucil
Lynkuet (elinzanetant)

+

chlorambucil

1 interaction

Caution Advised

elinzanetant + chlorambucil

caution advised: combo may incr. risk of seizures (additive effects)

• chlorpheniramine
Lynkuet (elinzanetant)

+

chlorpheniramine

1 interaction

Caution Advised

elinzanetant + chlorpheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorzoxazone
Lynkuet (elinzanetant)

+

chlorzoxazone

1 interaction

Caution Advised

elinzanetant + chlorzoxazone

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• cilostazol
Lynkuet (elinzanetant)

+

cilostazol

1 interaction

Caution Advised

elinzanetant + cilostazol

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• cimetidine
Lynkuet (elinzanetant)

+

cimetidine

1 interaction

Caution Advised

elinzanetant + cimetidine

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• citalopram
Lynkuet (elinzanetant)

+

citalopram

1 interaction

Caution Advised

elinzanetant + citalopram

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clemastine
Lynkuet (elinzanetant)

+

clemastine

1 interaction

Caution Advised

elinzanetant + clemastine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clomipramine
Lynkuet (elinzanetant)

+

clomipramine

1 interaction

Caution Advised

elinzanetant + clomipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, seizures (additive effects)

• clotrimazole oropharyngeal
Lynkuet (elinzanetant)

+

clotrimazole oropharyngeal

1 interaction

Caution Advised

elinzanetant + clotrimazole oropharyngeal

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• cobimetinib
Lynkuet (elinzanetant)

+

cobimetinib

1 interaction

Caution Advised

elinzanetant + cobimetinib

caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metab. inhibited)

• cranberry
Lynkuet (elinzanetant)

+

cranberry

1 interaction

Caution Advised

elinzanetant + cranberry

caution advised, especially w/ large amounts of cranberry: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metab. inhibited)

• cyclobenzaprine
Lynkuet (elinzanetant)

+

cyclobenzaprine

1 interaction

Caution Advised

elinzanetant + cyclobenzaprine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cyclophosphamide
Lynkuet (elinzanetant)

+

cyclophosphamide

1 interaction

Caution Advised

elinzanetant + cyclophosphamide

caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy (hepatic metab. possibly inhibited, decr. conversion to active metabolite)

• cyproheptadine
Lynkuet (elinzanetant)

+

cyproheptadine

1 interaction

Caution Advised

elinzanetant + cyproheptadine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dantrolene
Lynkuet (elinzanetant)

+

dantrolene

1 interaction

Caution Advised

elinzanetant + dantrolene

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darifenacin
Lynkuet (elinzanetant)

+

darifenacin

1 interaction

Caution Advised

elinzanetant + darifenacin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• desipramine
Lynkuet (elinzanetant)

+

desipramine

1 interaction

Caution Advised

elinzanetant + desipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• desvenlafaxine
Lynkuet (elinzanetant)

+

desvenlafaxine

1 interaction

Caution Advised

elinzanetant + desvenlafaxine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• deutetrabenazine
Lynkuet (elinzanetant)

+

deutetrabenazine

1 interaction

Caution Advised

elinzanetant + deutetrabenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexbrompheniramine
Lynkuet (elinzanetant)

+

dexbrompheniramine

1 interaction

Caution Advised

elinzanetant + dexbrompheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexchlorpheniramine
Lynkuet (elinzanetant)

+

dexchlorpheniramine

1 interaction

Caution Advised

elinzanetant + dexchlorpheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dichlorphenamide
Lynkuet (elinzanetant)

+

dichlorphenamide

1 interaction

Caution Advised

elinzanetant + dichlorphenamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difelikefalin
Lynkuet (elinzanetant)

+

difelikefalin

1 interaction

Caution Advised

elinzanetant + difelikefalin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difenoxin
Lynkuet (elinzanetant)

+

difenoxin

1 interaction

Caution Advised

elinzanetant + difenoxin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dihydroergotamine
Lynkuet (elinzanetant)

+

dihydroergotamine

1 interaction

Caution Advised

elinzanetant + dihydroergotamine

caution advised: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• dimenhydrinate
Lynkuet (elinzanetant)

+

dimenhydrinate

1 interaction

Caution Advised

elinzanetant + dimenhydrinate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diosmin
Lynkuet (elinzanetant)

+

diosmin

1 interaction

Caution Advised

elinzanetant + diosmin

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• diphenhydramine
Lynkuet (elinzanetant)

+

diphenhydramine

1 interaction

Caution Advised

elinzanetant + diphenhydramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diphenoxylate
Lynkuet (elinzanetant)

+

diphenoxylate

1 interaction

Caution Advised

elinzanetant + diphenoxylate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• doxepin
Lynkuet (elinzanetant)

+

doxepin

1 interaction

Caution Advised

elinzanetant + doxepin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• doxepin topical
Lynkuet (elinzanetant)

+

doxepin topical

1 interaction

Caution Advised

elinzanetant + doxepin topical

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dronabinol
Lynkuet (elinzanetant)

+

dronabinol

1 interaction

Caution Advised

elinzanetant + dronabinol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• duloxetine
Lynkuet (elinzanetant)

+

duloxetine

1 interaction

Caution Advised

elinzanetant + duloxetine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• eletriptan
Lynkuet (elinzanetant)

+

eletriptan

1 interaction

Caution Advised

elinzanetant + eletriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• entacapone
Lynkuet (elinzanetant)

+

entacapone

1 interaction

Caution Advised

elinzanetant + entacapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• eplerenone
Lynkuet (elinzanetant)

+

eplerenone

1 interaction

Caution Advised

elinzanetant + eplerenone

caution advised: combo may incr. eplerenone levels, risk of adverse effects (hepatic metab. inhibited)

• ergotamine
Lynkuet (elinzanetant)

+

ergotamine

1 interaction

Caution Advised

elinzanetant + ergotamine

caution advised: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• escitalopram
Lynkuet (elinzanetant)

+

escitalopram

1 interaction

Caution Advised

elinzanetant + escitalopram

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• eslicarbazepine acetate
Lynkuet (elinzanetant)

+

eslicarbazepine acetate

1 interaction

Caution Advised

elinzanetant + eslicarbazepine acetate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• ethinyl estradiol (contraceptive)
Lynkuet (elinzanetant)

+

ethinyl estradiol (contraceptive)

1 interaction

Caution Advised

elinzanetant + ethinyl estradiol (contraceptive)

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ethosuximide
Lynkuet (elinzanetant)

+

ethosuximide

1 interaction

Caution Advised

elinzanetant + ethosuximide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• felbamate
Lynkuet (elinzanetant)

+

felbamate

1 interaction

Caution Advised

elinzanetant + felbamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• fenfluramine
Lynkuet (elinzanetant)

+

fenfluramine

1 interaction

Caution Advised

elinzanetant + fenfluramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• fesoterodine
Lynkuet (elinzanetant)

+

fesoterodine

1 interaction

Caution Advised

elinzanetant + fesoterodine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fluoxetine
Lynkuet (elinzanetant)

+

fluoxetine

1 interaction

Caution Advised

elinzanetant + fluoxetine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fluvoxamine
Lynkuet (elinzanetant)

+

fluvoxamine

1 interaction

Caution Advised

elinzanetant + fluvoxamine

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• fosaprepitant
Lynkuet (elinzanetant)

+

fosaprepitant

1 interaction

Caution Advised

elinzanetant + fosaprepitant

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• foslevodopa
Lynkuet (elinzanetant)

+

foslevodopa

1 interaction

Caution Advised

elinzanetant + foslevodopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fostamatinib
Lynkuet (elinzanetant)

+

fostamatinib

1 interaction

Caution Advised

elinzanetant + fostamatinib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• frovatriptan
Lynkuet (elinzanetant)

+

frovatriptan

1 interaction

Caution Advised

elinzanetant + frovatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ganaxolone
Lynkuet (elinzanetant)

+

ganaxolone

1 interaction

Caution Advised

elinzanetant + ganaxolone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• gepotidacin
Lynkuet (elinzanetant)

+

gepotidacin

1 interaction

Caution Advised

elinzanetant + gepotidacin

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ginkgo
Lynkuet (elinzanetant)

+

ginkgo

1 interaction

Caution Advised

elinzanetant + ginkgo

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• givinostat
Lynkuet (elinzanetant)

+

givinostat

1 interaction

Caution Advised

elinzanetant + givinostat

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metab. inhibited)

• givosiran
Lynkuet (elinzanetant)

+

givosiran

1 interaction

Caution Advised

elinzanetant + givosiran

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, givosiran effects on hepatic heme biosynthesis may reduce CYP450 enzyme activity)

• glecaprevir
Lynkuet (elinzanetant)

+

glecaprevir

1 interaction

Caution Advised

elinzanetant + glecaprevir

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• glofitamab
Lynkuet (elinzanetant)

+

glofitamab

1 interaction

Caution Advised

elinzanetant + glofitamab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• glycopyrrolate
Lynkuet (elinzanetant)

+

glycopyrrolate

1 interaction

Caution Advised

elinzanetant + glycopyrrolate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• goldenseal
Lynkuet (elinzanetant)

+

goldenseal

1 interaction

Caution Advised

elinzanetant + goldenseal

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• grazoprevir
Lynkuet (elinzanetant)

+

grazoprevir

1 interaction

Caution Advised

elinzanetant + grazoprevir

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• guanfacine
Lynkuet (elinzanetant)

+

guanfacine

1 interaction

Caution Advised

elinzanetant + guanfacine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• haloperidol
Lynkuet (elinzanetant)

+

haloperidol

1 interaction

Caution Advised

elinzanetant + haloperidol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• hydroxychloroquine
Lynkuet (elinzanetant)

+

hydroxychloroquine

1 interaction

Caution Advised

elinzanetant + hydroxychloroquine

caution advised: combo may incr. risk of seizures (additive effects)

• hyoscyamine
Lynkuet (elinzanetant)

+

hyoscyamine

1 interaction

Caution Advised

elinzanetant + hyoscyamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iloperidone
Lynkuet (elinzanetant)

+

iloperidone

1 interaction

Caution Advised

elinzanetant + iloperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• imipramine
Lynkuet (elinzanetant)

+

imipramine

1 interaction

Caution Advised

elinzanetant + imipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• isoniazid
Lynkuet (elinzanetant)

+

isoniazid

1 interaction

Caution Advised

elinzanetant + isoniazid

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• istradefylline
Lynkuet (elinzanetant)

+

istradefylline

1 interaction

Caution Advised

elinzanetant + istradefylline

caution advised, especially w/ istradefylline 40 mg dose: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ivacaftor
Lynkuet (elinzanetant)

+

ivacaftor

1 interaction

Caution Advised

elinzanetant + ivacaftor

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lacosamide
Lynkuet (elinzanetant)

+

lacosamide

1 interaction

Caution Advised

elinzanetant + lacosamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• lamotrigine
Lynkuet (elinzanetant)

+

lamotrigine

1 interaction

Caution Advised

elinzanetant + lamotrigine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• lapatinib
Lynkuet (elinzanetant)

+

lapatinib

1 interaction

Caution Advised

elinzanetant + lapatinib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• larotrectinib
Lynkuet (elinzanetant)

+

larotrectinib

1 interaction

Caution Advised

elinzanetant + larotrectinib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lasmiditan
Lynkuet (elinzanetant)

+

lasmiditan

1 interaction

Caution Advised

elinzanetant + lasmiditan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lazertinib
Lynkuet (elinzanetant)

+

lazertinib

1 interaction

Caution Advised

elinzanetant + lazertinib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• levetiracetam
Lynkuet (elinzanetant)

+

levetiracetam

1 interaction

Caution Advised

elinzanetant + levetiracetam

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• levocetirizine
Lynkuet (elinzanetant)

+

levocetirizine

1 interaction

Caution Advised

elinzanetant + levocetirizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levodopa
Lynkuet (elinzanetant)

+

levodopa

1 interaction

Caution Advised

elinzanetant + levodopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levomilnacipran
Lynkuet (elinzanetant)

+

levomilnacipran

1 interaction

Caution Advised

elinzanetant + levomilnacipran

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• linvoseltamab
Lynkuet (elinzanetant)

+

linvoseltamab

1 interaction

Caution Advised

elinzanetant + linvoseltamab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lofexidine
Lynkuet (elinzanetant)

+

lofexidine

1 interaction

Caution Advised

elinzanetant + lofexidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• loxapine
Lynkuet (elinzanetant)

+

loxapine

1 interaction

Caution Advised

elinzanetant + loxapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lumacaftor/ivacaftor
Lynkuet (elinzanetant)

+

lumacaftor/ ivacaftor

1 interaction

Caution Advised

elinzanetant + lumacaftor/ ivacaftor

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• magnesium citrate
Lynkuet (elinzanetant)

+

magnesium citrate

1 interaction

Caution Advised

elinzanetant + magnesium citrate

caution advised, especially if magnesium citrate bowel prep use: combo may incr. risk of seizures (additive effects)

• maribavir
Lynkuet (elinzanetant)

+

maribavir

1 interaction

Caution Advised

elinzanetant + maribavir

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• mavorixafor
Lynkuet (elinzanetant)

+

mavorixafor

1 interaction

Caution Advised

elinzanetant + mavorixafor

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• meclizine
Lynkuet (elinzanetant)

+

meclizine

1 interaction

Caution Advised

elinzanetant + meclizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• melatonin
Lynkuet (elinzanetant)

+

melatonin

1 interaction

Caution Advised

elinzanetant + melatonin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• meprobamate
Lynkuet (elinzanetant)

+

meprobamate

1 interaction

Caution Advised

elinzanetant + meprobamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methocarbamol
Lynkuet (elinzanetant)

+

methocarbamol

1 interaction

Caution Advised

elinzanetant + methocarbamol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methsuximide
Lynkuet (elinzanetant)

+

methsuximide

1 interaction

Caution Advised

elinzanetant + methsuximide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• methyldopa
Lynkuet (elinzanetant)

+

methyldopa

1 interaction

Caution Advised

elinzanetant + methyldopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methylergonovine
Lynkuet (elinzanetant)

+

methylergonovine

1 interaction

Caution Advised

elinzanetant + methylergonovine

caution advised: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• metyrapone
Lynkuet (elinzanetant)

+

metyrapone

1 interaction

Caution Advised

elinzanetant + metyrapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrosine
Lynkuet (elinzanetant)

+

metyrosine

1 interaction

Caution Advised

elinzanetant + metyrosine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• milnacipran
Lynkuet (elinzanetant)

+

milnacipran

1 interaction

Caution Advised

elinzanetant + milnacipran

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• molindone
Lynkuet (elinzanetant)

+

molindone

1 interaction

Caution Advised

elinzanetant + molindone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mosunetuzumab
Lynkuet (elinzanetant)

+

mosunetuzumab

1 interaction

Caution Advised

elinzanetant + mosunetuzumab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mycophenolate mofetil
Lynkuet (elinzanetant)

+

mycophenolate mofetil

1 interaction

Caution Advised

elinzanetant + mycophenolate mofetil

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• naltrexone
Lynkuet (elinzanetant)

+

naltrexone

1 interaction

Caution Advised

elinzanetant + naltrexone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• naratriptan
Lynkuet (elinzanetant)

+

naratriptan

1 interaction

Caution Advised

elinzanetant + naratriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nicardipine
Lynkuet (elinzanetant)

+

nicardipine

1 interaction

Caution Advised

elinzanetant + nicardipine

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• nortriptyline
Lynkuet (elinzanetant)

+

nortriptyline

1 interaction

Caution Advised

elinzanetant + nortriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• orphenadrine
Lynkuet (elinzanetant)

+

orphenadrine

1 interaction

Caution Advised

elinzanetant + orphenadrine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• osilodrostat
Lynkuet (elinzanetant)

+

osilodrostat

1 interaction

Caution Advised

elinzanetant + osilodrostat

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• oxcarbazepine
Lynkuet (elinzanetant)

+

oxcarbazepine

1 interaction

Caution Advised

elinzanetant + oxcarbazepine

caution advised if seizure disorder use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• palbociclib
Lynkuet (elinzanetant)

+

palbociclib

1 interaction

Caution Advised

elinzanetant + palbociclib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• paliperidone
Lynkuet (elinzanetant)

+

paliperidone

1 interaction

Caution Advised

elinzanetant + paliperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• palovarotene
Lynkuet (elinzanetant)

+

palovarotene

1 interaction

Caution Advised

elinzanetant + palovarotene

caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metab. inhibited)

• paroxetine
Lynkuet (elinzanetant)

+

paroxetine

1 interaction

Caution Advised

elinzanetant + paroxetine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• passion flower
Lynkuet (elinzanetant)

+

passion flower

1 interaction

Caution Advised

elinzanetant + passion flower

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pazopanib
Lynkuet (elinzanetant)

+

pazopanib

1 interaction

Caution Advised

elinzanetant + pazopanib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• peppermint
Lynkuet (elinzanetant)

+

peppermint

1 interaction

Caution Advised

elinzanetant + peppermint

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• perampanel
Lynkuet (elinzanetant)

+

perampanel

1 interaction

Caution Advised

elinzanetant + perampanel

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• pheniramine
Lynkuet (elinzanetant)

+

pheniramine

1 interaction

Caution Advised

elinzanetant + pheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pibrentasvir
Lynkuet (elinzanetant)

+

pibrentasvir

1 interaction

Caution Advised

elinzanetant + pibrentasvir

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• pirtobrutinib
Lynkuet (elinzanetant)

+

pirtobrutinib

1 interaction

Caution Advised

elinzanetant + pirtobrutinib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• polyethylene glycol
Lynkuet (elinzanetant)

+

polyethylene glycol

1 interaction

Caution Advised

elinzanetant + polyethylene glycol

caution advised, especially if polyethylene glycol bowel prep use: combo may incr. risk of seizures (additive effects)

• polyethylene glycol/electrolytes
Lynkuet (elinzanetant)

+

polyethylene glycol/ electrolytes

1 interaction

Caution Advised

elinzanetant + polyethylene glycol/ electrolytes

caution advised: combo may incr. risk of seizures (additive effects)

• pramipexole
Lynkuet (elinzanetant)

+

pramipexole

1 interaction

Caution Advised

elinzanetant + pramipexole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• procarbazine
Lynkuet (elinzanetant)

+

procarbazine

1 interaction

Caution Advised

elinzanetant + procarbazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• prochlorperazine
Lynkuet (elinzanetant)

+

prochlorperazine

1 interaction

Caution Advised

elinzanetant + prochlorperazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• protriptyline
Lynkuet (elinzanetant)

+

protriptyline

1 interaction

Caution Advised

elinzanetant + protriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pyrilamine
Lynkuet (elinzanetant)

+

pyrilamine

1 interaction

Caution Advised

elinzanetant + pyrilamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• quercetin
Lynkuet (elinzanetant)

+

quercetin

1 interaction

Caution Advised

elinzanetant + quercetin

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• quetiapine
Lynkuet (elinzanetant)

+

quetiapine

1 interaction

Caution Advised

elinzanetant + quetiapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ramelteon
Lynkuet (elinzanetant)

+

ramelteon

1 interaction

Caution Advised

elinzanetant + ramelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ranolazine
Lynkuet (elinzanetant)

+

ranolazine

1 interaction

Caution Advised

elinzanetant + ranolazine

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• rasagiline
Lynkuet (elinzanetant)

+

rasagiline

1 interaction

Caution Advised

elinzanetant + rasagiline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• remdesivir
Lynkuet (elinzanetant)

+

remdesivir

1 interaction

Caution Advised

elinzanetant + remdesivir

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• resveratrol
Lynkuet (elinzanetant)

+

resveratrol

1 interaction

Caution Advised

elinzanetant + resveratrol

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• rifabutin
Lynkuet (elinzanetant)

+

rifabutin

1 interaction

Caution Advised

elinzanetant + rifabutin

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• rifampin
Lynkuet (elinzanetant)

+

rifampin

1 interaction

Caution Advised

elinzanetant + rifampin

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• risperidone
Lynkuet (elinzanetant)

+

risperidone

1 interaction

Caution Advised

elinzanetant + risperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ritlecitinib
Lynkuet (elinzanetant)

+

ritlecitinib

1 interaction

Caution Advised

elinzanetant + ritlecitinib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• rizatriptan
Lynkuet (elinzanetant)

+

rizatriptan

1 interaction

Caution Advised

elinzanetant + rizatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• roflumilast
Lynkuet (elinzanetant)

+

roflumilast

1 interaction

Caution Advised

elinzanetant + roflumilast

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

• roflumilast topical
Lynkuet (elinzanetant)

+

roflumilast topical

1 interaction

Caution Advised

elinzanetant + roflumilast topical

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metab. inhibited)

• ropinirole
Lynkuet (elinzanetant)

+

ropinirole

1 interaction

Caution Advised

elinzanetant + ropinirole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rotigotine transdermal
Lynkuet (elinzanetant)

+

rotigotine transdermal

1 interaction

Caution Advised

elinzanetant + rotigotine transdermal

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rucaparib
Lynkuet (elinzanetant)

+

rucaparib

1 interaction

Caution Advised

elinzanetant + rucaparib

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• rufinamide
Lynkuet (elinzanetant)

+

rufinamide

1 interaction

Caution Advised

elinzanetant + rufinamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• safinamide
Lynkuet (elinzanetant)

+

safinamide

1 interaction

Caution Advised

elinzanetant + safinamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• scopolamine
Lynkuet (elinzanetant)

+

scopolamine

1 interaction

Caution Advised

elinzanetant + scopolamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selegiline
Lynkuet (elinzanetant)

+

selegiline

1 interaction

Caution Advised

elinzanetant + selegiline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selegiline transdermal
Lynkuet (elinzanetant)

+

selegiline transdermal

1 interaction

Caution Advised

elinzanetant + selegiline transdermal

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selinexor
Lynkuet (elinzanetant)

+

selinexor

1 interaction

Caution Advised

elinzanetant + selinexor

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sertraline
Lynkuet (elinzanetant)

+

sertraline

1 interaction

Caution Advised

elinzanetant + sertraline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sirolimus topical
Lynkuet (elinzanetant)

+

sirolimus topical

1 interaction

Caution Advised

elinzanetant + sirolimus topical

caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metab. inhibited)

• sodium picosulfate
Lynkuet (elinzanetant)

+

sodium picosulfate

1 interaction

Caution Advised

elinzanetant + sodium picosulfate

caution advised: combo may incr. risk of seizures (additive effects)

• solifenacin
Lynkuet (elinzanetant)

+

solifenacin

1 interaction

Caution Advised

elinzanetant + solifenacin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• spironolactone
Lynkuet (elinzanetant)

+

spironolactone

1 interaction

Caution Advised

elinzanetant + spironolactone

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. possibly inhibited)

• St. John's wort
Lynkuet (elinzanetant)

+

St. John's wort

1 interaction

Caution Advised

elinzanetant + St. John's wort

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• stiripentol
Lynkuet (elinzanetant)

+

stiripentol

1 interaction

Caution Advised

elinzanetant + stiripentol

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metab. inhibited, additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• sulfate bowel prep
Lynkuet (elinzanetant)

+

sulfate bowel prep

1 interaction

Caution Advised

elinzanetant + sulfate bowel prep

caution advised: combo may incr. risk of seizures (additive effects)

• sumatriptan
Lynkuet (elinzanetant)

+

sumatriptan

1 interaction

Caution Advised

elinzanetant + sumatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tasimelteon
Lynkuet (elinzanetant)

+

tasimelteon

1 interaction

Caution Advised

elinzanetant + tasimelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tetrabenazine
Lynkuet (elinzanetant)

+

tetrabenazine

1 interaction

Caution Advised

elinzanetant + tetrabenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiotepa
Lynkuet (elinzanetant)

+

thiotepa

1 interaction

Caution Advised

elinzanetant + thiotepa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tiagabine
Lynkuet (elinzanetant)

+

tiagabine

1 interaction

Caution Advised

elinzanetant + tiagabine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• ticagrelor
Lynkuet (elinzanetant)

+

ticagrelor

1 interaction

Caution Advised

elinzanetant + ticagrelor

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• tizanidine
Lynkuet (elinzanetant)

+

tizanidine

1 interaction

Caution Advised

elinzanetant + tizanidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolcapone
Lynkuet (elinzanetant)

+

tolcapone

1 interaction

Caution Advised

elinzanetant + tolcapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolterodine
Lynkuet (elinzanetant)

+

tolterodine

1 interaction

Caution Advised

elinzanetant + tolterodine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• topiramate
Lynkuet (elinzanetant)

+

topiramate

1 interaction

Caution Advised

elinzanetant + topiramate

caution advised if seizure disorder use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• trazodone
Lynkuet (elinzanetant)

+

trazodone

1 interaction

Caution Advised

elinzanetant + trazodone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• treosulfan
Lynkuet (elinzanetant)

+

treosulfan

1 interaction

Caution Advised

elinzanetant + treosulfan

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, seizures, other adverse effects (hepatic metab. inhibited, additive effects)

• trifluoperazine
Lynkuet (elinzanetant)

+

trifluoperazine

1 interaction

Caution Advised

elinzanetant + trifluoperazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trihexyphenidyl
Lynkuet (elinzanetant)

+

trihexyphenidyl

1 interaction

Caution Advised

elinzanetant + trihexyphenidyl

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimipramine
Lynkuet (elinzanetant)

+

trimipramine

1 interaction

Caution Advised

elinzanetant + trimipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• triprolidine
Lynkuet (elinzanetant)

+

triprolidine

1 interaction

Caution Advised

elinzanetant + triprolidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trofinetide
Lynkuet (elinzanetant)

+

trofinetide

1 interaction

Caution Advised

elinzanetant + trofinetide

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metab. inhibited)

• trospium
Lynkuet (elinzanetant)

+

trospium

1 interaction

Caution Advised

elinzanetant + trospium

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valbenazine
Lynkuet (elinzanetant)

+

valbenazine

1 interaction

Caution Advised

elinzanetant + valbenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valerian
Lynkuet (elinzanetant)

+

valerian

1 interaction

Caution Advised

elinzanetant + valerian

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valproic acid
Lynkuet (elinzanetant)

+

valproic acid

1 interaction

Caution Advised

elinzanetant + valproic acid

caution advised if seizure disorder use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• venlafaxine
Lynkuet (elinzanetant)

+

venlafaxine

1 interaction

Caution Advised

elinzanetant + venlafaxine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vigabatrin
Lynkuet (elinzanetant)

+

vigabatrin

1 interaction

Caution Advised

elinzanetant + vigabatrin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

• vilazodone
Lynkuet (elinzanetant)

+

vilazodone

1 interaction

Caution Advised

elinzanetant + vilazodone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• viloxazine
Lynkuet (elinzanetant)

+

viloxazine

1 interaction

Caution Advised

elinzanetant + viloxazine

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• vonoprazan
Lynkuet (elinzanetant)

+

vonoprazan

1 interaction

Caution Advised

elinzanetant + vonoprazan

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• xanomeline
Lynkuet (elinzanetant)

+

xanomeline

1 interaction

Caution Advised

elinzanetant + xanomeline

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metab. possibly inhibited)

• zileuton
Lynkuet (elinzanetant)

+

zileuton

1 interaction

Caution Advised

elinzanetant + zileuton

caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ziprasidone
Lynkuet (elinzanetant)

+

ziprasidone

1 interaction

Caution Advised

elinzanetant + ziprasidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolmitriptan
Lynkuet (elinzanetant)

+

zolmitriptan

1 interaction

Caution Advised

elinzanetant + zolmitriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zonisamide
Lynkuet (elinzanetant)

+

zonisamide

1 interaction

Caution Advised

elinzanetant + zonisamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)